Arteris, Inc. SEC Filings

Form 144 notice for Arteris, Inc. (AIP) reports a proposed sale of 10,000 common shares to be executed through Morgan Stanley Smith Barney on 09/15/2025 with an aggregate market value of $87,500. The filer acquired these shares the same day by exercise of stock options and paid in cash. The filing also discloses insider sales over the prior three months totaling 9,448 shares for aggregate gross proceeds of $85,168.03, executed under both regular and Rule 10b5-1 plans. The notice includes the filer’s representation that no undisclosed material adverse information is known.

Arteris, Inc. (AIP) reporting person Nicholas B. Hawkins, Vice President and Chief Financial Officer, reported a sale of common stock on 09/09/2025 under a Rule 10b5-1 trading plan adopted June 4, 2025. The filing shows 3,660 shares were sold at a weighted average price of $8.6903, with the filing noting individual sale prices ranged from $8.51 to $8.83. After the reported sale, Mr. Hawkins beneficially owned 103,898 shares, held directly. The Form 4 was signed by an attorney-in-fact on 09/10/2025. The disclosure emphasizes the transaction was pursuant to a pre-established trading plan and offers to provide detailed per-price sale breakdowns upon request.

Paul L. Alpern, Vice President and General Counsel of Arteris, Inc. (AIP), reported sales of company common stock under a 10b5-1 plan. On 09/08/2025 he sold 424 shares at $8.98 per share, and on 09/09/2025 he sold 2,278 shares at a weighted average price of $8.689 per share. After these transactions he beneficially owned 73,587 shares. The Form 4 states the sales were made pursuant to a trading plan adopted June 5, 2025, and provides a price range of $8.51 to $8.82 for the multiple trades comprising the weighted average.

Arteris, Inc. (AIP) insider Form 4 summary: The company's Chief Operating Officer, Laurent R. Moll, reported multiple sales of common stock in early September 2025 executed pursuant to a 10b5-1 trading plan adopted March 12, 2025. On 09/05/2025 she sold 4,698 shares at a weighted average price of $8.8045, reducing her beneficial ownership to 394,681 shares. On 09/08/2025 she sold 8,129 shares at a weighted average price of $8.7434, reducing beneficial ownership to 386,552 shares. On 09/09/2025 she sold 151 shares at $8.61, leaving 386,401 shares beneficially owned. The Form 4 was signed by an attorney-in-fact.

Arteris, Inc. (AIP) Form 144 notice reports a proposed sale of 2,278 common shares with an aggregate market value of $19,568.02. The shares represent part of the company's 42,649,917 outstanding common shares and are scheduled for sale on 09/09/2025 through Morgan Stanley Smith Barney LLC on NASDAQ. The filer acquired these shares as Restricted Stock Units on 04/01/2025, with payment dated the same day. The filing also lists four secondary sales by the same person in the prior three months totaling 6,170 shares for gross proceeds of $65,374.37.

Arteris, Inc. (AIP) Form 144 reports a proposed sale of 3,660 common shares with an aggregate market value of $31,439.40, scheduled approximately for 09/09/2025 through NASDAQ by broker Morgan Stanley Smith Barney LLC. The shares were acquired as Restricted Stock Units from the issuer on 04/01/2025. The filing lists prior sales by the same person, Nicholas Hawkins, including multiple 10b5-1 plan transactions from 06/25/2025 through 09/02/2025 totaling several tens of thousands of shares and proceeds shown per trade.

Janac K Charles, President and CEO of Arteris, Inc. (AIP) and a director with 10% ownership, reported a planned sale of common stock executed on 09/04/2025 under a 10b5-1 trading plan adopted March 5, 2025. The reported transaction shows 2,057 shares sold at a weighted average price of $8.7255, with individual sale prices ranging from $8.5750 to $8.8900.

Following the sale, the reporting person beneficially owns 186,482 shares directly and indirectly holds 9,839,071 shares through Bayview Legacy, LLC and 56,252 shares through the Charles and Lydia Janac Trust. The filer provided the standard footnote offering to supply detailed per-price sale information on request.

Arteris, Inc. (AIP) Form 144: An insider intends to sell 424 shares of common stock through Morgan Stanley Smith Barney, scheduled approximately 09/08/2025, with an aggregate market value reported as $3,756.64. The filing reports those 424 shares were acquired as restricted stock units on 09/01/2025. The filing also discloses prior dispositions by the same person during the past three months: 258 shares on 09/02/2025 (gross proceeds $2,306.96) and two July sales totaling 6,488 shares (gross proceeds $59,259.89), including a 10b5-1 plan sale of 3,609 shares on 07/03/2025. The filer certifies no undisclosed material information.

Arteris, Inc. (AIP) filed a Form 144 reporting a planned sale of 12,978 common shares valued at $114,725.52, representing part of ~42.65 million shares outstanding, with an approximate sale date of 09/05/2025 on NASDAQ. The shares were acquired as restricted stock units on 09/01/2025 and are scheduled for sale the same month. The filing also discloses sales by Laurent Moll totaling 84,380 shares for aggregate gross proceeds of $915,838.75 over the past three months, including transactions executed under a 10b5-1 plan. The filer certifies no undisclosed material adverse information.